Immunic Inc [IMUX] stock prices are down -6.15% to $1.83 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The IMUX shares have gain 20.39% over the last week, with a monthly amount glided 12.27%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, B. Riley Securities started tracking the stock with Buy rating on August 27, 2024, and set its price target to $6. On October 21, 2022, downgrade downgraded it’s rating to Mkt Perform but maintained its price target of $5 on the stock. Aegis Capital initiated its recommendation with a Buy and recommended $55 as its price target on April 15, 2021. JMP Securities started tracking with a Mkt Outperform rating for this stock on March 24, 2021, and assigned it a price target of $55. In a note dated October 02, 2020, SVB Leerink initiated an Outperform rating and provided a target price of $45 on this stock.
The stock price of Immunic Inc [IMUX] has been fluctuating between $0.95 and $2.11 over the past year. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Immunic Inc [NASDAQ: IMUX] shares were valued at $1.83 at the most recent close of the market. An investor can expect a potential return of 173.22% based on the average IMUX price forecast.
Analyzing the IMUX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.1, Equity is -1.7 and Total Capital is -1.47. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.7466 points at the first support level, and at 1.6632 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.9967, and for the 2nd resistance point, it is at 2.1634.
Ratios To Look Out For
It’s worth pointing out that Immunic Inc [NASDAQ:IMUX]’s Current Ratio is 3.75. On the other hand, the Quick Ratio is 3.75, and the Cash Ratio is 3.51.
